Weight Loss Plateaus on GLP-1 Medication

A weight loss plateau on Mounjaro, Wegovy or another GLP-1 medicine is common and, in most cases, expected. Short stalls of a few weeks happen to almost everyone, and in clinical trials average weight loss levelled off after about a year to eighteen months as the body reached a new balance. A plateau doesn't usually mean the medicine has stopped working. Sometimes there is something practical to adjust, and sometimes a prescriber may review your dose or plan. This guide explains why plateaus happen, what the evidence shows, and the options to discuss with a professional.

What counts as a plateau?

People use "plateau" to describe different things, and the distinction matters for what, if anything, should change.

Most worries are about the middle three categories. The first is simply noise, and the last is often what success looks like on long-term treatment.

Why plateaus happen

Your body needs less energy as you lose weight

A smaller body uses less energy at rest and during activity. As you lose weight, the calorie gap that drove early weight loss gradually narrows, even if you are eating the same amount. Eventually, intake and expenditure meet at a new, lower weight.

Biological push-back

When people lose weight, the body responds with changes in appetite hormones and energy use that encourage regaining it. This is one reason obesity is considered a chronic, relapsing condition. GLP-1 medicines help counteract some of these signals, but they don't remove them entirely. Our guide to obesity as a chronic disease explores this.

Dose and titration

In the first months, you are on gradually increasing doses designed to limit side effects. Weight loss is often slower during this phase. A plateau during titration may simply mean you haven't yet reached the dose that suits you, which is a decision your prescriber will make as you progress. Our guides to the Mounjaro dosing schedule and Wegovy dosing schedule describe the standard steps.

Changes in eating as side effects settle

Early in treatment, nausea and fullness can reduce how much people eat. As the body adjusts, these effects often ease, appetite returns a little, and portion sizes can creep up without people noticing.

Lifestyle and other factors

Other common contributors include:

• Drinking more alcohol or sugary drinks, which provide calories without much fullness
• Grazing or more frequent snacking
• Less physical activity, sometimes because of tiredness from eating less
• Poor sleep or stress
• New medicines that can affect weight, such as some antidepressants, antipsychotics, steroids or insulin
• Hormonal changes, including those around the menopause
• Fluid retention, for example around menstruation

Gaining muscle

If you have started resistance training, you may gain some muscle while losing fat. The scales may stay level even though your body composition and waist measurement are improving. This is a good outcome, not a plateau in the sense that matters.

What the trials show about plateaus

Major trials show a consistent pattern: steady weight loss over the first months, slowing over time, and levelling off at around 60 to 72 weeks.

Two lessons stand out:

1. Levelling off is the norm, not the exception. Even in tightly run trials with maximum doses, average weight loss eventually stabilised.
2. Continuing treatment keeps weight down. In STEP 4 and SURMOUNT-4, people who stopped the medicine regained a substantial amount of weight. This tells us the medicine is still working during the plateau phase; it is helping to hold the new weight.

Practical things to review

Before considering any change to medicine, it can help to look at a few everyday factors. This isn't about blame; many of these changes happen gradually and without notice.

Eating patterns

• Protein. Prioritising protein at each meal helps with fullness and preserving muscle. See our guide to protein on GLP-1 medication.
• Portion drift. As appetite returns, portions can creep up. Using smaller plates or noting what you eat for a week can be revealing.
• Liquid calories. Alcohol, juices, smoothies, specialty coffees and sugary drinks add up quickly.
• Grazing. Small, frequent snacks can add more than expected.
• Ultra-processed foods. These are easy to eat quickly and often less filling for their calories.

Our guide to what to eat on GLP-1 medication offers practical ideas.

Activity

• Regular movement helps maintain weight loss and supports heart health, mood and sleep.
• Resistance or strength exercise two or more days a week, as recommended in UK physical activity guidelines, helps preserve muscle.
• Gradual increases are more sustainable than sudden ambitious plans.

See our guides on exercise on GLP-1 medication and preserving muscle.

Sleep and stress

Short or poor-quality sleep and ongoing stress are associated with increased appetite and cravings. Improving sleep routines can help, and untreated sleep apnoea is worth discussing with your GP.

Medicines and health conditions

If you have started a new medicine around the time weight loss stalled, mention it to your prescriber. Some conditions, such as an underactive thyroid, can also affect weight.

How you are measuring

Weigh yourself under similar conditions, for example in the morning after using the toilet, and look at the trend over several weeks rather than single readings. Measuring your waist and noting changes in clothes, fitness or blood results can show progress the scales miss. See our guide to measuring progress beyond the scales.

Clinical options a prescriber may consider

If a plateau persists and you want to lose more weight, your prescriber may review your treatment. These are decisions for them, based on your health, side effects and goals, and the options below are for information only.

Reviewing your dose

If you are below the maximum licensed dose and tolerating treatment well, your prescriber may consider an increase. The maximum licensed dose of Mounjaro is 15 mg weekly. For Wegovy, the standard maintenance dose is 2.4 mg weekly, and in January 2026 the MHRA approved a maximum dose of up to 7.2 mg weekly for adults with obesity (BMI of 30 or more), based on the STEP UP trial. That higher dose does not apply to people with a BMI under 30 or to people using Wegovy for cardiovascular risk reduction. Availability may vary, so check the current SmPC.

Higher doses aren't right for everyone. More side effects are possible, and if you are already at a dose that controls appetite well, increasing it may add little.

Considering a different medicine

In the SURMOUNT-5 trial, tirzepatide led to more average weight loss than semaglutide. For someone who has plateaued on Wegovy at a modest loss, a prescriber might discuss whether Mounjaro is worth considering. Switching has its own considerations; see our guides to switching from Wegovy to Mounjaro and switching from Mounjaro to Wegovy.

Additional support

Some people benefit from structured support, such as dietitian input, a weight management programme or psychological support around eating. NHS specialist services offer this as part of a wider programme, and some private providers include it.

Reassessing goals

If you have lost a meaningful amount and your health markers have improved, your prescriber may suggest that your current weight is a reasonable maintenance target. Even 5–10% weight loss is associated with meaningful health benefits for many people, such as improvements in blood pressure, blood glucose and joint pain.

You can compare the support offered by different regulated providers on our providers page.

Plateau or non-response?

A plateau after good weight loss is different from not responding to treatment at all. NICE guidance for NHS treatment (TA875 for semaglutide and TA1026 for tirzepatide) suggests reviewing treatment if less than 5% of starting weight has been lost after six months on the highest tolerated dose. If that sounds more like your situation, see our guide on what to do if GLP-1 treatment doesn't work for you.

For more on this topic, explore our plateau guides and the wider guides library. You may also find our Mounjaro results timeline helpful for context on what happens when.

Myths about GLP-1 plateaus

Plateaus attract a lot of online advice, not all of it accurate. Here are some common claims and what the evidence suggests.

"Your body has become immune to the medicine"

There is no good evidence that people develop tolerance to the appetite effects of GLP-1 medicines in the way the word "immune" suggests. Weight loss slowing is mainly explained by the body reaching a new balance at a lower weight. Trials of withdrawal, such as STEP 4 and SURMOUNT-4, show the medicine is still working during this phase, because weight rises when it is stopped.

"Eating very little will restart weight loss"

Severely restricting food can backfire. It increases the risk of muscle loss, nutritional deficiencies, fatigue, gallstones and, for people taking insulin or sulfonylureas, low blood sugar. It can also make eating patterns harder to sustain. A balanced approach focused on protein, fibre and regular meals is generally more sensible. See our guide on what to eat on GLP-1 medication.

"Skipping a dose will 'shock' your body"

Some online forums suggest pausing doses to break a plateau. There is no evidence that this works, and missing doses can reduce appetite control, cause regain and mean you need to restart at a lower dose with side effects returning. Take your medicine as prescribed.

"Cheat days reset your metabolism"

There is no robust evidence that planned high-calorie days reset metabolism in a way that helps weight loss. On GLP-1 medicines, large meals are also more likely to cause nausea, vomiting or reflux.

"A plateau means you've failed"

A plateau is a normal stage of treatment, not a personal failure. If you have lost a meaningful amount of weight and your health has improved, maintaining that loss is itself an achievement.

Patience and perspective

It is easy to compare your progress with others online or with trial averages. Remember:

• Trial results are averages across thousands of people, and individual journeys look very different.
• Weight loss is rarely a straight line. Even people who lose a lot of weight in total have weeks where nothing seems to change.
• A plateau after losing 10% or more of your starting weight puts you in a range associated with meaningful health benefits for many people.
• Your health markers, fitness and wellbeing may continue to improve even when your weight is stable.

If plateaus are affecting your mood or motivation, it can help to talk them through with your prescriber or GP. Our guide to realistic weight loss expectations puts trial figures in context.

A simple plateau checklist

Before your next review, it may help to run through these questions and bring the answers with you:

This gives your prescriber a clear picture and helps them decide whether any change to your treatment is appropriate.

Plateaus and cost

If you are paying privately, a plateau can raise questions about value, especially if you are considering a higher dose. Higher doses may cost more, and prices have changed over time, including after the September 2025 rise in the UK list price of Mounjaro. It is reasonable to discuss cost openly with your prescriber alongside clinical factors. We don't quote prices in guides, but you can compare services on our prices page and read our guide to the long-term cost of GLP-1 treatment.

When a plateau is actually maintenance

For people who have been on treatment for more than a year, a long plateau is often what doctors would describe as successful maintenance. In SURMOUNT-4 and STEP 4, people who continued treatment after their initial loss largely held their new weight, and some lost a little more. That is the expected pattern for long-term treatment.

Thinking of this phase as maintenance rather than failure can be helpful. The goals shift from losing more to:

• Keeping your weight stable within a range agreed with your prescriber
• Preserving muscle through protein and strength exercise
• Maintaining improvements in blood pressure, blood glucose and other health markers
• Finding a dose that controls appetite with as few side effects as possible
• Planning for the long term, including cost and monitoring

Our guides to long-term GLP-1 use and Mounjaro maintenance explain this phase in more detail.

When to speak to a professional

Speak to your prescriber, GP or pharmacist if:

• Your weight has been stable for more than two to three months and you want to lose more
• You have regained weight without an obvious reason
• You have started a new medicine around the time your weight changed
• You feel very tired, cold, low in mood or have other new symptoms that could suggest a health condition
• You are thinking about increasing your dose or changing medicine
• You are finding it hard to eat enough, or are worried about your relationship with food

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, which may spread to your back, with or without vomiting
• Repeated vomiting with signs of dehydration, such as dizziness or very dark urine
• Yellowing of the skin or eyes, or upper right abdominal pain with fever
• Signs of a severe allergic reaction, such as swelling of the face or throat, or difficulty breathing